HIGHLIGHTS
- who: Ribo Tang and colleagues from the Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China, National Clinical Research have published the research work: The Antiarrhythmic Mechanisms of Flecainide in Catecholaminergic Polymorphic Ventricular Tachycardia, in the Journal: (JOURNAL)
- what: Flecainide has a significant impact on the clinical management of patients with CPVT.
SUMMARY
Clinical phenotypes include catecholamine-associated syncope and a characteristic pattern of bidirectional VT in the absence of structural heart disease (Leenhardt et_al, 1995; Liu et_al, 2008; Priori et_al, 2013). The primary treatment strategy for CPVT is . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.